Retatrutide is tested head to head against semaglutide in Phase 3 TRANSCEND-T2D-2
The ClinicalTrials.gov record for TRANSCEND-T2D-2, Eli Lilly and Company's Phase 3 open-label study of once-weekly retatrutide compared with once-weekly semaglutide in adults with type 2 diabetes, was verified in September 2026 as active and no longer recruiting.
What is retatrutide?
Retatrutide (development code LY3437943) is an investigational, once-weekly injectable peptide from Eli Lilly that activates three receptors at once: GLP-1, GIP, and glucagon.
Read the full guide →In 30 seconds
- The study compares retatrutide with semaglutide, used as an active comparator, in adults with type 2 diabetes inadequately controlled on a stable regimen of metformin, at or above the protocol's minimum daily dose, with or without an SGLT2 inhibitor.
- Two retatrutide dose levels are listed, both given subcutaneously, against one semaglutide arm; there is no masking and about 1,250 participants are planned.
- The primary measure is change from baseline in HbA1c at week 80, with percent change in body weight among the other measures.
Why it matters
TRANSCEND-T2D-2 sets retatrutide, given once weekly, against once-weekly semaglutide as an active comparator, rather than against an inactive control, in adults whose type 2 diabetes is inadequately controlled with metformin, with or without a sodium-glucose cotransporter-2 inhibitor. The sponsor is Eli Lilly and Company, and the stated purpose is to investigate the efficacy and safety of retatrutide compared with semaglutide in that population.
The registry also shows how the comparison will be judged: change from baseline in HbA1c at week 80 is the primary measure, and percent change from baseline in body weight is among the additional measures, alongside the share of participants reaching defined HbA1c and weight-reduction thresholds.
The details
- Design: a Phase 3, randomized, multicenter, open-label study, with parallel assignment, treatment as its primary purpose and no masking.
- Arms: two experimental retatrutide dose levels, both administered subcutaneously, and one semaglutide arm listed as the active comparator, also administered subcutaneously. Retatrutide appears in the record under the other name LY3437943.
- Planned size: an estimated enrollment of about 1,250 participants. Duration: the record states the study will last about 26 months and may include up to 24 visits.
- Primary measure: change from baseline in hemoglobin A1c (HbA1c), assessed from baseline to week 80.
- Other measures at week 80: percent change from baseline in body weight, the percentage of participants achieving HbA1c at or below 6.5% and the percentage achieving HbA1c below 5.7%, the percentages achieving weight reduction of at least 5%, at least 10% and at least 15%, and the percentage achieving both HbA1c at or below 6.5% and at least 10% weight reduction.
- Also measured: percent change from baseline in triglycerides, percent change from baseline in non-high-density lipoprotein cholesterol, and change from baseline in systolic blood pressure.
- Who can take part: adults aged 18 years and older with type 2 diabetes, HbA1c of at least 7.0% (53 mmol/mol) up to 10.5% (91 mmol/mol), a body mass index of at least 25.0 kg/m2, stable weight for at least 90 days before screening, and a stable diabetes treatment consisting of metformin at or above the minimum daily dose set by the protocol, with or without an SGLT2 inhibitor, during the 90 days before screening.
- Who is excluded: among other criteria, people with type 1 diabetes, a prior or planned surgical treatment for obesity, chronic or acute pancreatitis, a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, an active or untreated malignancy (or remission from a clinically significant malignancy for less than five years), any lifetime history of a suicide attempt, and anyone who took medication or alternative remedies intended to promote weight reduction in the 90 days before screening.
What it does not change
This is a registry record, not a result and not a regulatory decision. It sets out what the study will measure rather than reporting any outcome, so no conclusion can be drawn yet about how retatrutide performs against semaglutide on HbA1c, body weight, lipids or blood pressure. The design is open-label, with masking listed as none, which is a limitation to keep in mind when results do appear. Nothing in the record changes the approved status of either molecule in any country.
What's next
The record lists the study as active and no longer recruiting, with the status verified in September 2026, so attention now turns to the week 80 readout of the primary HbA1c measure and the secondary weight and cardiometabolic measures. Eli Lilly and Company states that anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement, with data available six months after the primary publication or approval of the indication studied in the US and EU, whichever is later.
What we don't know yet
The registry gives no efficacy or safety figures, so the size of any difference between the two molecules is unknown, as is whether the two retatrutide dose levels behave differently; the record identifies them only as dose level 1 and dose level 2. It also does not say how the open-label design will be handled in the analysis, and it reports no data on how either molecule compares with any other treatment. The study is described as investigating efficacy and safety, which remains the open question until results are published.
Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.
Source documents
This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.